**RESEARCH ARTICLE**

**PARS risk charts: A 10-year study of risk assessment for cardiovascular diseases in Eastern Mediterranean Region**

Nizal Sarrafzadegan1,2‡, Razieh Hassannejad3*, Hamid Reza Marateb4,5*, Mohammad Talaei1,6‡, Masoumeh Sadeghi11, Hamid Reza Roohafza1‡, Farzad Masoudkabir7,8, Shahram OveisGharan9,10, Marjan Mansourian3*, Mohammad Reza Mohebian4, Miquel Angel Mañanas6,11

1 Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran, 2 School of Population and Public Health, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada, 3 Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran, 4 Biomedical Engineering Department, Engineering Faculty, University of Isfahan, Isfahan, Iran, 5 Department of Automatic Control, Biomedical Engineering Research Center, Universitat Politècnica de Catalunya, BarcelonaTech (UPC), Barcelona, Spain, 6 Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, 7 Department of Cardiology, School of Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran, 8 Cardiac Primary Prevention Research Center, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran, 9 Department of Neurology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, 10 Rush Alzheimer’s disease Center; Rush University Medical Center, Chicago, Illinois, United States of America, 11 Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, Spain

* These authors also contributed equally to this work.
‡ These authors also contributed equally to this work.
* j_mansourian@hhth.mui.ac.ir

**Abstract**

This study was designed to develop a risk assessment chart for the clinical management and prevention of the risk of cardiovascular disease (CVD) in Iranian population, which is vital for developing national prevention programs. The Isfahan Cohort Study (ICS) is a population-based prospective study of 6504 Iranian adults ≥35 years old, followed-up for ten years, from 2001 to 2010. Behavioral and cardiometabolic risk factors were examined every five years, while biennial follow-ups for the occurrence of the events was performed by phone calls or by verbal autopsy. Among these participants, 5432 (2784 women, 51.3%) were CVD free at baseline examination and had at least one follow-up. Cox proportional hazard regression was used to predict the risk of ischemic CVD events, including sudden cardiac death due to unstable angina, myocardial infarction, and stroke. The model fit statistics such as area under the receiver-operating characteristic (AUROC), calibration chi-square and the overall bias were used to assess the model performance. We also tested the Framingham model for comparison. Seven hundred and five CVD events occurred during 49452.8 person-years of follow-up. The event probabilities were calculated and presented color-coded on each gender-specific PARS chart. The AUROC and Harrell’s C indices were 0.74 (95% CI, 0.72–0.76) and 0.73, respectively. In the calibration, the Nam-D’Agostino $\chi^2$ was 10.82 ($p = 0.29$). The overall bias of the proposed model was 95.60%. PARS model was also internally validated using cross-validation. The Android app and the Web-based
risk assessment tool were also developed as to have an impact on public health. In comparison, the refitted and recalibrated Framingham models, estimated the CVD incidence with the overall bias of 149.60% and 128.23% for men, and 222.70% and 176.07% for women, respectively. In conclusion, the PARS risk assessment chart is a simple, accurate, and well-calibrated tool for predicting a 10-year risk of CVD occurrence in Iranian population and can be used in an attempt to develop national guidelines for the CVD management.

Introduction

Recent guidelines on the primary prevention of cardiovascular disease (CVD) in clinical practice stress the urgency of having a necessary preventive intervention procedure regarding the absolute risk of CVD rather than assessment of any particular risk factors such as blood pressure and/or cholesterol levels [1]. Indeed, researchers have started to believe that hypertension is not a proper term to use. Also, the term “risk” should be applied instead of “risk factors” by the future Clinicians [2, 3]. However, most cardiovascular risk factors cannot be categorized based on the presence or absence of the risk, mostly synergistic effects of the risk factors should be considered; there is no absolute risk and the effects of the risk factors are proportional. Data from a North American study evaluating Clinicians’ ability to quantify CVD risk and treatment benefits, recommends that both general practitioners and specialist physicians substantially overestimate the CVD risk and benefits of treatment [4]. As a result, the statistical prediction of future cardiovascular events has received increased attention in recent years.

Several well-known models and charts of CVD risk assessment have been developed and updated in the past five decades, including the Framingham risk score [5], the pooled cohort equations recommended by the American College of Cardiology (ACC) in 2013, American Heart Association (AHA) cardiovascular risk-assessment guidelines [1], and the SCORE [6], ASSIGN [7], Q-Risk [8], PROCAM [9] and Globorisk [10, 11] risk prediction models. A growing body of evidence indicates that risk prediction scores lead to improvement in risk management [2]. However, the constitution of risk chart is based on the risk factors outline, which is distinct in different populations. Consequently, the risk assessment charts are specific for each population and cannot be used in different populations [12]. Hence, the design of specific risk-assessment models for different populations depends on parameters measured from the local population and this seems necessary for optimizing the risk assessment for individuals within the specific population [12].

On the report of the World Health Organization, the Middle Eastern countries are anticipated to have the highest incidence of diabetes, and in case of CVD till 2020 [13, 14]. As one of the Middle Eastern countries, Iran has alarming incidence rates of CVD and the associated risk factors [15, 16]. However, there are small data from longitudinal studies, assessing the impact of CVD risk factors among Iranian population, limited to specific areas [17]. To the best of our knowledge, no CVD risk prediction score has been specifically developed for the Iranian population to date, which is vital for developing national CVD management and prevention programs. Given the importance of developing local risk assessment tools, we used the Isfahan cohort study (ICS) dataset [14], a 10-year population-based longitudinal study started in 2001 with the main goal of developing the Persian Atherosclerotic cardiovascular disease Risk Stratification (PARS) charts in Iran. The study was performed by Isfahan Cardiovascular Research Center (ICRC), a WHO-collaborating center (http://apps.who.int/whocc/Detail.aspx?cc_ref=IRA-23&ccc_code=ira).
**Materials and methods**

### Study population

The ICS is a longitudinal population-based study, with 6504 adult subjects aged $\geq 35$ years at the baseline examination, enrolled in 2001 using multistage random cluster sampling [18]. The subjects living in three Iranian central areas (Arak, Isfahan, and Najafabad), enrolled in the Isfahan Healthy Heart Program (IHHP), were recruited for ICS [14, 19]. The IHHP design was previously reported [20]. Isfahan is a city with a population of 1986542, the second most populous metropolitan area in Iran after Tehran. In 2006, the population of Arak and Najafabad, was 555975 and 282430, respectively. These areas were selected because of the socioeconomic, demographic picture and health profile similarities to the other large cities in Iran. The overall prevalence of CVD was estimated as 19.4% in Isfahan [21], which was almost similar to that of Tehran, the capital of Iran (21.8%) [22].

Participants were recruited from 2001 and followed-up for at least ten years. All subjects signed the informed consent form for the experimental procedure. Ethics approval was obtained from the Isfahan Cardiovascular Research Center Ethics Committee, a WHO collaborating center in the Eastern Mediterranean Region (EMR), and Isfahan University of Medical Sciences and conformed to the Declaration of Helsinki. For controlling selection bias, the samples were randomly selected from a healthy population. The participants were selected by multistage random cluster sampling. The study population was first stratified by their living area (urban vs rural). We then randomly selected census blocks from each county and divided them into clusters. Within each cluster, households were randomly selected for enumeration. From each household, we randomly selected one eligible individual. The inclusion criteria were as follows: being Iranian, aged $\geq 19$ years, mentally competent, and not pregnant. The exclusion criteria were: having a stroke, ischemic heart attack, coronary heart disease, and heart failure.

Meanwhile, the random sampling was used without any restriction for the elderly, as to overcome underestimation or volunteer bias [16]. These subjects were followed up until CVDs occurred. All participants had no clinical history of chronic diseases and were interviewed by trained personnel (registered Nurses, Dietitians and General Practitioners), using standard questionnaires assessing lifestyle habits, various sociodemographic predictors, and clinical or biological characteristics. They were followed up by repeating these measurements every five years, and biennially by phone calls looking for the occurrence of any of primary or secondary events. However, as it happens in cohort studies, there were lost to follow-up participants in each of these follow-up phases (Fig 1). An important reason for the loss to follow-up was a change in phone numbers, based on the government new policy in the whole country. It was part of a network capacity expansion policy, without any particular distribution. It was thus completely random, not biasing the follow-up [14].

### Risk factor measurements

Participants were interviewed by trained personnel to complete standardized questionnaires, including questions on cardiovascular risk factors, and also clinical examinations, electrocardiography and laboratory evaluation [19].

After sitting for five minutes, trained physicians measured the blood pressure by standard mercury Sphygmomanometers, using the right arm of resting participants. Blood pressure measurements were repeated after 15 minutes, and the average of two measures was reported. While shoes were removed, height was measured to the closest centimeter by a trained technician. A calibrated scale was used to measure weight in light clothing. Weight (kg) was divided
by height in squared meter (m²), and represented as body mass index (BMI). The smallest circumference at or below the costal margin was taken as waist circumference (WC). The hip circumference was taken at the level of the greater trochanter.

Fasting (12 h) blood samples (FBS) were taken from the participants. The entire samples were frozen at −20°C, in order to be assayed within 72 hours at the central laboratory of the
ICRC, meeting the criteria of the WHO-collaborating center. Moreover, it was under the external quality control of St. Rafael University, Leuven and Belgium [18]. A 2-hour post-load plasma glucose (2 hpp) test was performed, using the samples from entire participants, without including diabetic subjects. DNA samples and serums were frozen at -70˚C, for further analysis.

A cell counter AL820 was used to measure hematological parameters. An auto-analyzer (Eppendorf, Hamburg, Germany) was used to enzymatically measure total serum cholesterol (TC), triglycerides (TG) and FBS. In subjects with TG <400 mg/dl, the Friedewald equation was used to calculate serum low-density lipoprotein cholesterol (LDL-C), and in other cases, standard kits’ instructions were followed. Low-density and very low-density lipoproteins were precipitated, using dextran sulfate-magnesium, and then serum high-density lipoprotein-cholesterol (HDL-C) was measured [21].

Event criteria

Since 2001, each participant has been followed up for every two years. In 2007, full structured interview, clinical and blood-sample testing were repeated as the baseline examination. Telephone interviews were implemented in 2003, 2005, 2007, 2009 and 2011 and if they were deceased, attempts were made to contact all living participants or their first-degree relatives. When the phone interviews were unsuccessful, the participants were visited at their home address for the follow-up. Structured questionnaire was asked based on being alive, hospitalized and experiencing specific neurological symptoms. The date of death, hospitalization or neurological symptoms, physician diagnosis and the hospital’s name were obtained during the interview [14]. For deaths out of hospital, death registries from the provincial mortality database were used to obtain death certificates. Verbal autopsies were performed before death by a trained Nurse based on predefined questionnaire, including medical history, signs and symptoms. Additional secondary interviews for hospitalized cases were performed where information was incomplete or inconsistent.

When there were not any inconsistent dates or diagnosis, or the records were not obtainable, we used the original medical records of MI and stroke registry database of the Surveillance Department of ICRC, to verify the reported events. If we were not able to find hospitalization data in the database, trained Nurses investigated the medical records [14].

A professional panel, consisting of Cardiologists and Neurologists have reviewed all the documents and made a decision about the diagnosis of each CVD event. Such events were defined as either acute coronary syndromes, consisting of fatal or non-fatal myocardial infarction and unstable angina, sudden cardiac death, and fatal or non-fatal stroke. The detailed description of the above-mentioned end points, risk factor measurements, and data collection have been provided in the previous reports [14, 15, 19].

Statistical methods

CVD risk function. The development of the risk function in ICS was assessed, according to the following three steps: I) Refitted Framingham function: multiple Cox (proportional-hazards) regression models were derived, using the same variables of Framingham equation and ICS database. II) Recalibration of Framingham function: in these functions, the $\beta$ coefficients were taken from the Framingham model, but the mean values and the incidence rates of the risk factors were taken from the ICS cohort. III) PARS function, i.e. the proposed new model in this study [5]. The regression models were first fitted one-at-a-time to a broad set of risk factors separately, including age, sex, TC, TG, systolic blood pressure (SBP), diastolic blood pressure (DBP), HDL-C, LDL-C, TC\HDL-C ratio, LDL-C\HDL-C ratio, TC\TG ratio, LDL-C\TG
ratio, BMI, waist to hip ratio (WHR), WC, smoking status and diabetes. The most important risk factors were then hierarchically included in the model based on the higher hazard ratio (HR). At each step, significant risk factors remained in the model. The final model, referred to PARS risk function, had the best discrimination and calibration (The protocol: dx.doi.org/10.17504/protocols.io.j7rcrm6).

After testing the assumption of proportionality, cox proportional hazards model was used. The Schoenfeld residuals were used for testing the proportional hazards (PH) assumption for risk factors. Further evaluation was applied to check the PH assumption, regarding the risk factors plotted graphically with the log-cumulative hazard plots as a function of survival time, comparing Kaplan-Meier survival estimates and Cox adjusted estimates plotted on the same graph. If the graphical approaches suggested that there is some violation of PH assumption, an extended cox model was run based on an appropriate function of survival time. It was performed by defining the product term involving time-independent variable with some function of time (g(t) or Heaviside function) and testing the coefficient of the product term. In our analysis, there was no significant coefficient of the time-dependent variable based on product terms.

The Cox regression model was used to estimate the absolute 10-year risk of CVD (P) as follows:

\[
P = 1 - S(t)\exp\{f(x, M)\} = \sum_{i=1}^{N} \beta_i(x_i - M_i)
\]

where S(t) is the survival rate calculated at the mean risk factor values, \(M_i\) are the mean risk factor values in the ICS, \(\beta_i\) are the regression coefficients, \(x_i\) represents risk factors and \(N\) is the number of compartments in the model.

**Model performance assessment.** A two-tailed z statistic was used to compare the hazard ratios in the ICS and Framingham functions [22, 23], in which

\[
z = (b_F - b_I)/SE(b_F - b_I)
\]

\[
SE(b_F - b_I) = \sqrt{SE_{b_F}^2 + SE_{b_I}^2},
\]

where \(b_F\) and \(b_I\) are the \(\beta\) coefficient of the Framingham and ICS model, respectively with \(SE_{b_F}\) and \(SE_{b_I}\), as the standard errors (SEs) of \(b_F\) and \(b_I\).

The degree of discrimination power of the model was assessed, using AUROC or C-statistic and Harrell’s C. The Nam-D’Agostino chi-square test was used for evaluating time-to-event analysis calibration [24].

**Validation procedures.** Two internal validation (resampling) methods namely as 10-fold cross-validation and bootstrapping were used to obtain unbiased estimates of predictive accuracy. The above two techniques are used to assess, if the developed risk scores could be generalized to an independent data set. In this method, the data set is randomly divided into ten equal size groups. Among which, the model is tested on a single validation group, while the model is estimated, using the other nine groups (training data). Such validation is then repeated ten times, in which each of the groups is used one time, for validation. Then the average of ten validations was calculated. Moreover, internal bootstrapping was used to obtain unbiased estimates of predictive accuracy. Fifty thousand random samples were bootstrapped. Finally, overall bias in predicting CVD incidence was estimated as [13, 25]:

\[
\text{overall bias(%) = } \left( \frac{\text{Predicted incidence - Observed incidence}}{\text{Observed incidence}} \right) \times 100
\]

We applied a risk threshold, people with risk higher than 20% were considered high risk by recent guidelines [1, 26–28].
**Risk chart.** We constructed 10-year risk assessment charts of CVD incidence, using important risk factors. Such a user-friendly chart included SBP, WHR, diabetes, smoking status, CVD family history and TC. SBP was grouped into four classes: (1) $<120$, (2) $120–139$, (3) $140–159$, and (4) $\geq 160$ mm Hg. These cutoff points were based on National Cholesterol Education Program’s Adult Treatment Panel III (ATP III). TC was categorized into five groups: (1) $<150$, (2) $150–200$, (3) $200–250$, (4) $250–300$ and (5) $\geq 300$ mg/dl. High waist-to-hip ratio (WHR) was defined as WHR $\geq 0.80$ and 0.95 in women and men, respectively. When FBS $\geq 126$ mg/dl or the 2h post-load plasma glucose $\geq 200$ mg/dl or the patient was receiving anti-diabetic agents, the subject were diagnosed with diabetes mellitus. The smoking variable comprised of current smokers.

The following CVD probabilities ($\leq 1\%$, $2\%$, $3\%–4\%$, $5\%–9\%$, $10\%–14\%$ and $\geq 15\%$) were displayed on the risk chart and color-coded.

Statistical modeling and analysis were performed, using SAS software, version 9.3 (SAS Institute Inc). Matlab version 8.6 (The MathWorks Inc., Natick, MA, USA) was used for risk chart generation and model validations.

Our missing data were missing at random (MAR). We thus used multivariate imputation by a chained equation’s method in STATA 12.0 for managing the measurements with missing data. The baseline characteristics and the prevalence of CVD risk factors were compared, among lost to follow-up and loyal subjects, using the sensitivity analysis. Participants without any event and loss to follow-up events were considered as censored.

**Results**

The response rate of house interview was 98%, but only 95% attended the examination clinic. The main reasons for not participating were related to address and or phone number change, and to a less extent, not willing to take part in multiple follow-ups. There were 181 (2.8%) cases with CVD events excluded from the ICS baseline examination. A number of 891 (14.1%) participants were missed before the first follow-up. The loss to follow-up rate was 404 (6.4%), 249 (3.9%), 87 (1.4%) and 104 (1.6%) in the second through the fifth stage of follow-ups, respectively (Fig 1). The prevalence of the CVD risk factors and also baseline characteristics were not significantly different between lost to follow-ups and loyal subjects [14, 16].

**Baseline risk factors**

The Baseline examination of participant risk factors is shown in Table 1. The Average age for men and women was 51.2±11.9 and 50.3±11.3 years, respectively. The majority of women have a high WHR (94.6%). In comparison with women, the smoking rate was far greater in men (41.6% vs. 3.3%). The SBP level has almost similar frequency distribution in men and women. Higher levels of TC were more prevalent in women, compared to men. The prevalence of diabetes mellitus was less in men, compared with women (9.3 vs. 12.6).

**Cardiovascular events**

A total of 705 CVD events (564 IHDs, 141 strokes) occurred, during 49452.8 follow-ups person-years (minimum 0.1, maximum 10.9 years). IHD comprised of 39 (20 women and 19 men) fatal and 113 (36 women and 77 men) non-fatal MI, 331 (171 women and 160 men) UA, and 81 (26 women and 55 men) sudden cardiac deaths. Ischemic stroke composed of 30 (16 women and 14 men) fatal and 111 cases (57 women and 54 men) of non-fatal stroke. The total CVD event rates were 1.6 per 100 person-year for men and 1.3 per 100 person-year for women, without adjusting for age. Follow-up person-years, CVD events, and the levels of risk factors of the baseline examination are shown in Table 2.
Refitted and recalibration of Framingham function

The CVD risk factor regression coefficients and HRs were estimated from sex-specific ICS regression models, using the same variables as those in the Framingham function (Table 3). During the discriminatory analysis, the AUROC was 0.730 (95% CI, 0.703–0.757) and 0.754.

Table 1. Baseline characteristics of the study participants, ICS, 2001–2011.

| Risk factors                        | Men (N = 2648) | Women (N = 2784) |
|-------------------------------------|---------------|------------------|
| High waist to hip ratio<sup>a</sup> | 39.2          | 94.6             |
| Systolic blood pressure (mm/Hg)     |                |                  |
| <120                                | 44.4          | 44.9             |
| 120–139                             | 37.1          | 33.7             |
| 140–159                             | 12            | 13.4             |
| >=160                               | 6.6           | 8                |
| Total cholesterol (mg/dl)           |                |                  |
| <150                                | 11.4          | 7.5              |
| 150–200                             | 35            | 30.4             |
| 200–250                             | 34.1          | 36.4             |
| 250–300                             | 14.2          | 18.6             |
| >300                                | 5.2           | 7.2              |
| Diabetes                            | 9.3           | 12.6             |
| Smoker                              | 41.6          | 3.3              |
| Family history of CVD               | 5             | 5.7              |
| Age (years) (Mean±SD)               | 51.15±11.93   | 50.27±11.32      |

CVD: cardiovascular disease; SD: standard deviation.
<sup>a</sup> Waist-to-hip ratio (WHR) ≥ 0.80 in women and ≥ 0.95 in men was considered as a high WHR.

https://doi.org/10.1371/journal.pone.0189389.t001

Table 2. Person-years of follow-up and CVD events according to risk factors in men and women, ICS, 2001–2011.

|                     | Men          |            | Women         |            |
|---------------------|--------------|------------|---------------|------------|
|                     | Person-years of follow-up | CVD events | Person-years of follow-up | CVD events |
| Total               | 23931        | 379        | 25522         | 326        |
| High waist to hip ratio<sup>a</sup> | 9190.1 | 214 | 24037.4 | 314 |
| Systolic blood pressure (mm/Hg) |              |            |               |            |
| <120                | 11132.3      | 96         | 11652         | 67         |
| 120–139             | 8741.5       | 148        | 8746.2        | 116        |
| 140–159             | 2683         | 76         | 3347.7        | 78         |
| >=160               | 1374.1       | 59         | 1776.1        | 65         |
| Total cholesterol (mg/dl) |              |            |               |            |
| <150                | 2826.4       | 27         | 1917          | 15         |
| 150–200             | 8507.1       | 112        | 7938.5        | 71         |
| 200–250             | 8144.3       | 131        | 9206.3        | 123        |
| 250–300             | 3253.8       | 79         | 4710.25       | 77         |
| >300                | 1198.9       | 30         | 1749.8        | 40         |
| Diabetes            | 2059.8       | 82         | 3040.7        | 87         |
| Smoker              | 9809.1       | 159        | 805.3         | 18         |
| Family history of CVD | 1205.7   | 22         | 1415.8        | 27         |

CVD: cardiovascular disease
<sup>a</sup> Waist-to-hip ratio (WHR) ≥ 0.95 in men and ≥ 0.8 in women was considered as a high WHR.

https://doi.org/10.1371/journal.pone.0189389.t002
(95% CI, 0.727–0.781), for men and women, respectively. In the calibration, the Nam-D’Agostino $\chi^2$ was 24.29 ($p = 0.004$) and 7.28 ($p = 0.61$) for men and women, respectively. The ICS refitted Framingham model significantly overestimated the CVD incidence with the overall bias of 149.60% and 222.70% in men and women, respectively. The 10-fold cross-validation yielded a mean AUROC of 0.73 (95% CI, 0.70–0.76) and 0.75 (95% CI, 0.72–0.77) in men and women, respectively.

The C statistic value for the recalibrated Framingham function applied to ICS was 0.700 (95% CI, 0.671–0.729) and 0.748 (95% CI, 0.721–0.775) for CVD prediction in men and women, respectively. The recalibrated Framingham model overestimated the CVD incidence with the overall bias of 128.23% and 176.07% in men and women, respectively. The 10-fold cross-validation yielded a mean AUROC of 0.70 (95% CI, 0.67–0.73) and 0.75 (95% CI, 0.72–0.77) in men and women, respectively.

### PARS risk function

Having considered the variety of predictors and their interactions in a multivariate Cox regression, significant predictors of CVD events were age, sex, high WHR, SBP level, TC level, diabetes mellitus, smoking status and family history of CVD. The optimal PARS model is presented in Table 4.

The value of AUROC was 0.74 (95% confidence interval [CI], 0.72–0.76) and Harrell’s C was 0.73. In the calibration, the Nam-D’Agostino $\chi^2$ was 10.82 ($p = 0.004$) and 12.19 ($p = 0.14$) for men and women, respectively. The recalibrated Framingham model underestimated the CVD incidence with the overall bias of 128.23% and 176.07% in men and women, respectively. The 10-fold cross-validation yielded a mean AUROC of 0.70 (95% CI, 0.67–0.73) and 0.75 (95% CI, 0.72–0.77) in men and women, respectively.

### Table 3. Comparison of relative risk and performance of ICS and Framingham.

|                  | ICS cohort                  | Framingham cohort              |
|------------------|-----------------------------|---------------------------------|
| **Women**        |                             |                                 |
| Log of age       | 180.05 (47.45–683.21)       | 10.27 (5.65–18.64)              |
| Log of total cholesterol | 3.26 (1.02–10.38)       | 3.35 (2.00–5.62)                |
| Log of HDL cholesterol | 0.33 (0.10–1.07)       | 0.49 (0.35–0.69)                |
| Log of SBP if not treated | 57.76 (9.97–334.44)  | 15.82 (7.86–31.87)              |
| Log of SBP if treated | 70.47 (10.77–464.87)  | 16.82 (8.46–33.46)              |
| Smoking          | 1.53 (0.95–2.47)            | 1.70 (1.40–2.06)                |
| Diabetes         | 1.87 (1.45–2.40)            | 2.00 (1.49–2.67)                |
| **C statistics** | $\chi^2 = 7.84 (p = 0.55)$ | $\chi^2 = 7.79 (p = 0.56)$     |
| **Men**          |                             |                                 |
| Log of age       | 92.37 (27.69–308.21)        | 21.35 (14.03–32.48)             |
| Log of total cholesterol | 6.20 (2.36–16.27)      | 3.08 (2.05–4.62)                |
| Log of HDL cholesterol | 0.48 (0.16–1.44)       | 0.39 (0.30–0.52)                |
| Log of SBP if not treated | 29.08 (5.58–151.54) | 6.91 (3.91–12.20)               |
| Log of SBP if treated | 34.32 (5.72–205.92) | 7.38 (4.22–12.92)               |
| Smoking          | 1.28 (1.04–1.57)            | 1.92 (1.65–2.24)                |
| Diabetes         | 1.84 (1.42–2.38)            | 1.78 (1.43–2.20)                |
| **C statistics** | $\chi^2 = 20.05 (p = 0.02)$ | $\chi^2 = 13.48 (p = 0.14)$     |

https://doi.org/10.1371/journal.pone.0189389.t003
The 10-fold cross-validation, yielded a mean AUROC of 0.74 (95% CI; 0.72–0.76). In boot-strap validation, the mean AUROC was 0.74 (min-max; 0.70–0.78). Accordingly, PARS model could be internally validated. Moreover, the overall bias of the proposed model was 95.60%. PARS risk assessment charts were then created (Figs 3–6).

Table 4. Adjusted HRs for CVD risk factors using PARS risk function, ICS, 2001–2011.

| Risk factors       | Estimate | Hazard Ratio | 95% CI          |
|--------------------|----------|--------------|-----------------|
| Age                | 0.03759  | 1.038        | 1.031–1.045     |
| Male               | 0.28957  | 1.335        | 1.111–1.508     |
| Total cholesterol  |          |              |                 |
| <150\(^a\)         | -        | -            |                 |
| 150–200            | 0.20759  | 1.231        | 0.879–1.723     |
| 200–250            | 0.34201  | 1.408        | 1.013–1.957     |
| 250–300            | 0.45316  | 1.573        | 1.113–2.225     |
| >300               | 0.54847  | 1.731        | 1.172–2.556     |
| Systolic blood pressure |        |              |                 |
| <120\(^a\)         | -        | -            |                 |
| 120–139            | 0.45643  | 1.578        | 1.291–1.929     |
| 140–159            | 0.73967  | 2.09         | 1.651–2.644     |
| >=160              | 1.0467   | 2.848        | 2.207–3.876     |
| Diabetes           | 0.63041  | 1.878        | 1.570–2.247     |
| High waist to hip ratio\(^b\) | 0.26989  | 1.31         | 1.072–1.601     |
| Family history of CVD | 0.40182  | 1.495        | 1.116–2.002     |
| Smoking            | 0.28974  | 1.336        | 1.104–1.617     |

CI, confidence interval; \(^a\) reference category
\(^b\) Waist-to-hip ratio (WHR) ≥ 0.80 in women and ≥ 0.95 in men was considered as a high WHR.

https://doi.org/10.1371/journal.pone.0189389.t004

The 10-fold cross-validation, yielded a mean AUROC of 0.74 (95% CI; 0.72–0.76). In boot-strap validation, the mean AUROC was 0.74 (min-max; 0.70–0.78). Accordingly, PARS model could be internally validated. Moreover, the overall bias of the proposed model was 95.60%. PARS risk assessment charts were then created (Figs 3–6).

Fig 2. Comparison between observed and estimated 10-year risk of CVD using the PARS risk function.

https://doi.org/10.1371/journal.pone.0189389.g002
For instance, the estimated 10-year absolute CVD risk for a non-diabetic, non-smoker man aged 45 years, with high WHR, SBP of 145 mm Hg, TC of 205 mg/dl, and a positive family history of CVD would be 6%, as shown by the light red color (Fig 6).

Discussion
ICS is the first longitudinal population-based study, primarily designed to develop a CVD risk assessment tool (PARS), in Iran and EMR. ICS is being organized in three geographic areas with a large urban and rural population [14]. We developed the PARS, as a new CVD risk prediction tool in Iran, in preparation for a major change in national policy, by identifying the patients at high risk of CVD.

Framingham prediction algorithms have been comprehensively used, in the United States and other countries [29–31]. However, white middle class subjects were considered in such studies. Thus, the generalized findings could not be applied, in principle, to other low- and middle-income countries [14]. Such limitations of the Framingham risk function in diverse populations were well-documented. The Framingham scores had overestimated risk in the number of populations [6,32–34]. Consistently, our result also indicated that Framingham function overestimated risks in ICS population. We also found out that the ICS refitted and recalibrated Framingham were not so different in the prediction of CVD events. Also, central
obesity and family history of CVD are independent risk factors for CVD events in the ICS population, which can be used as additive covariates, improving the model; a better calibration was found in the model.

Recently, Globorisk models, a pooled analysis of prospective cohorts and health study in different countries, in which a study from IRAN was used for validation, was introduced in the literature [10, 11]. In Globorisk models, no risk chart was provided for IRAN, and the national study used by the authors only included participants aged \( \geq 65 \) years. Thus, it was not included for comparison.

Our method estimated the total CV event risk rather than the risk of CHD and/or stroke alone, not consistent with the earlier version of the Framingham risk score and the risk prediction models, originated from China [23], India [35], Turkey [36], Israel [37], Singapore [38], South Korea [39], and Chile [40]. As the aforementioned models were restricted to risk of coronary heart disease (CHD) [12] and also the PROCAM score [9], not consistent with our model, calculate the risk of CHD and stroke, separately. By calculating total CV risk, including the 10-year risk of fatal or non-fatal myocardial infarction, unstable angina, sudden cardiac death, and fatal or non-fatal stroke, we anticipate to provide a better risk estimate. Accordingly, WHO and current stress practice guidelines prefer to consider the total risk in making decisions about treatments [1, 26, 41, 42].

Fig 4. PARS charts for prediction of 10-year risk of fatal and non-fatal cardiovascular disease in ICS population with higher WHR and no CVD family history, 2001–2011.

https://doi.org/10.1371/journal.pone.0189389.g004
Based on a large Iranian representative population, we created a PARS chart. The PARS charts are user-friendly and color-coded (Figs 3–6). Furthermore, using a 6-color gradient from brown as the highest risk, to green as the lowest probability of CVD event, which help not only the Physicians but also the individuals to see their position on the chart [43].

It is known that diabetes is positively associated with the CVD risk. One of the limitations of the Framingham risk score is the small number of diabetic people in a cohort of 5573 individuals (4%) and also the diabetes definition was based on a random blood glucose concentration >9 mmol/l or the use of anti-glycemic treatment. Hence, the accuracy of the Framingham risk score for CV risk assessment in diabetic patients has been addressed in previous studies [44]. The most widely used risk score in the European countries, SCORE [6], also lacks the risk prediction power of diabetes because of the unavailability of data on diabetes, from some cohorts and also due to non-uniform definitions of diabetes, among other cohorts of the European population. In our new risk assessment charts for Iranian population, diabetes is a critical classifying risk factor due to being positioned, among the risk factors with highest HRs for the prediction of 10-year risk of CV events (Table 4). Moreover, there were 598 subjects (11%) with diabetes in our cohort (Table 1), in contrast to lower number in Framingham, making our risk estimates in diabetic patients more reliably.
While WHO [45] and the US National Heart, Lung and Blood Institute [46] recommend the assessment of WC in people with a BMI of 25.0–34.9 kg/m², the majority of generally used CVD risk scores did not consider obesity measures (e.g. Framingham, SCORE, PROCAM), but it was considered only by a few scores like QRISK [47, 48]. The INTERHEART study, a large multinational retrospective study of acute myocardial infarction in 52 countries, reported that WHR was three times more strongly related to the risk of acute myocardial infarction than BMI [49]. However, these reports have not been tested in prospective studies. In our model, high WHR was accounted for significant HR (1.31), and seems to be an important risk factor in our population (Table 4). The inclusion of BMI and WC in our model or position of WHR did not improve the model performance. Our findings in this large prospective study support and expand those of the INTERHEART study, which includes data from Asian and Middle Eastern countries, in addition to western data.

It was shown in the literature that the obesity prevalence is higher in developing countries, compared with Asian countries [45]. These conclusions are mainly based on BMI values. However, if WHR is used to define obesity, such prevalence significantly increases, specifically in the Middle East [49]. Furthermore, there is strong evidence that for a given WC, Asians have higher levels of intra-abdominal adiposity, obesity-related metabolic consequences (dyslipidemia, insulin resistance, and diabetes) and mortality, compared to whites [50, 51]. It may partly
justify why central obesity indices should be evaluated for CVD risk assessment in Asian and Middle Eastern countries [51]. Unlike the majority of the current risk prediction models, our data underscore the importance of WHR in the risk assessment and primary prevention of CVD (Tables 1 and 4).

We used TC because it can be measured more easily and cost-effectively than HDL or LDL cholesterol, and it is therefore measured more often in low-income and middle-income countries [10].

Our further analysis indicated other factors, including HDL-C, LDL-C, TC\HDL-C ratio, high LDL-C, LDL-C\HDL-C ratio, TC\TG ratio, LDL-C\TG ratio, and the interaction term of hypertriglyceridemia and low HDL-C, were relatively less important and were not associated with performance improvement in either gender.

Because of the following considerations, caution should be taken when the inclusion criteria of the present study are applied. (I) The study was based on the data from subjects with no CVD, and the models should not be directly applied to subjects with CVD. (II) Similar to the previous cohort studies worldwide [12], this study included individuals aged ≥35 years and therefore young adults were under-represented. Careful attention needs to be paid to the application of data for young individuals. Moreover, our charts only estimate the risk of CV event within a 10-year period.

The following ICS limitations must be considered: We underestimated the vascular diseases because stable diseases, such as heart failure, and vascular dementia and also peripheral vascular diseases were not included. Although accurate clinical data obtained from the hospital, the participants’ report of neurological symptoms was used to diagnose stroke when hospital admission was not found in the medical records. Such a verbal history is probably not accurate for CHD diagnosis [16]. Moreover, although the current study has distinctive coverage, in comparison with other similar national studies, but the samples were limited to the central area of Iran. Since, the estimated risk is dependent on the prevalence of the risk factors (Eq 1), therefore it is necessary for the proposed model to be externally validated, using other ethnic groups.

We speculate that PARS is likely to provide more appropriate estimates of CVD risk in the contemporary Iranian population with suitable discrimination for those who are at high risk in regard to age, sex, smoking status, diabetes, SBP, TC and WHR. PARS can serve as a useful tool in developing future national guidelines for the primary prevention of CVD (Figs 3–6). Furthermore, we anticipate that it could be applied in other countries in the EM region better than the western risk assessment scores.

Preparing the online prediction tool and its mobile app were also considered. The programming language used in PARS chart developed website was JavaScript and Bootstrap [52]. The JavaScript programming language has been widely used, for web programming and general purpose computing. The Android app was powered by Android Studio and API level 19 that can be used for Android 4.2 or higher version [53]. The Android app and Web-based program are freely accessible at www.prognosis.ir/PARS/index.php.

Supporting information
S1 Supporting Information. Different evaluated risk assessment models. (PDF)

Acknowledgments
This cohort study was conducted at the ICRC, affiliated with the Isfahan University of Medical Sciences (IUMS). We are grateful to the ICRC team, Isfahan Provincial Health Center, Najaf-
Abad Health Office and Arak University of Medical Sciences. The authors gratefully acknowledge the contribution of all participants.

**Author Contributions**

**Conceptualization:** Nizal Sarrafzadegan, Marjan Mansourian.

**Data curation:** Razieh Hassannejad, Mohammad Talaei, Marjan Mansourian.

**Formal analysis:** Razieh Hassannejad, Hamid Reza Marateb, Marjan Mansourian.

**Funding acquisition:** Nizal Sarrafzadegan, Miquel Angel Mañanas.

**Investigation:** Mohammad Talaei, Masoumeh Sadeghi, Hamid Reza Roohafza, Farzad Masoudkabir, Shahram OveisGharan.

**Methodology:** Razieh Hassannejad, Hamid Reza Marateb, Mohammad Talaei, Masoumeh Sadeghi, Hamid Reza Roohafza, Farzad Masoudkabir, Shahram OveisGharan, Marjan Mansourian, Mohammad Reza Mohebian, Miquel Angel Mañanas.

**Project administration:** Nizal Sarrafzadegan, Marjan Mansourian.

**Resources:** Nizal Sarrafzadegan.

**Software:** Razieh Hassannejad, Mohammad Reza Mohebian.

**Supervision:** Nizal Sarrafzadegan, Marjan Mansourian.

**Validation:** Hamid Reza Marateb.

**Visualization:** Hamid Reza Marateb, Mohammad Reza Mohebian.

**Writing – original draft:** Nizal Sarrafzadegan, Razieh Hassannejad, Hamid Reza Marateb.

**Writing – review & editing:** Mohammad Talaei, Masoumeh Sadeghi, Hamid Reza Roohafza, Farzad Masoudkabir, Shahram OveisGharan, Marjan Mansourian, Mohammad Reza Mohebian, Miquel Angel Mañanas.

**References**

1. Goff JDC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino SRB, Gibbons R, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2014; 63(25_PA).

2. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet (London, England). 2005 Jan 29-Feb 4; 365(9457):434–41. Epub 2005/02/01. eng.

3. Bozorgmanesh M, Hadaegh F, Azizi F. Predictive accuracy of the ‘Framingham’s general CVD algorithm’ in a Middle Eastern population: Tehran Lipid and Glucose Study. International journal of clinical practice. 2011; 65(3):264–73. https://doi.org/10.1111/j.1742-1241.2010.02529.x PMID: 21314863

4. Friedmann PD, Brett AS, Mayo-Smith MF. Differences in generalists’ and cardiologists’ perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Annals of internal medicine. 1996 Feb 15; 124(4):414–21. Epub 1996/02/15. eng. PMID: 8554250

5. D’Agostino RB Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008 Feb 12; 117 (6):743–53. Epub 2008/01/24. eng. https://doi.org/10.1161/CIRCULATIONAHA.107.699579 PMID: 18212285

6. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European heart journal. 2003 Jun; 24 (11):987–1003. Epub 2003/06/06. eng. PMID: 12788299
7. Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007 February 1; 93(2):172–6. https://doi.org/10.1136/hrt.2006.108167 PMID: 17090561

8. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ (Clinical research ed). 2007 Jul 21; 335(7611):136. Epub 2007/07/07. eng.

9. Assmann G, Cullen P, Schulte H. Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study. Circulation. 2002; 105(3):310–5. PMID: 11804985

10. Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA, et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. The Lancet Diabetes & Endocrinology. 2015; 3(5):339–55.

11. Ueda P, Woodward M, Lu Y, Hajifathalian K, Al-Wotayan R, Aguilar-Salinas CA, et al. Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys. The Lancet Diabetes & Endocrinology. 2017; 5(3):196–213.

12. Zhao D, Liu J, Xie W, Qi Y. Cardiovascular risk assessment: a global perspective. Nature reviews Cardiology. 2015 May; 12(5):301–11. Epub 2015/03/11. eng. https://doi.org/10.1038/nrcardi.2015.28 PMID: 25754885

13. Bozorgmanesh M, Hadaegh F, Ghaffari S, Harati H, Azizi F. A simple risk score effectively predicted type 2 diabetes in Iranian adult population: population-based cohort study. The European Journal of Public Health. 2011; 21(5):564–9. https://doi.org/10.1093/eurpub/cqp074 PMID: 20534889

14. Sarrafzadegan N, Talaei M, Sadeghi M, Kelishadi R, Oveisgharani S, Mohammadifar N, et al. The Isfahan cohort study: rationale, methods and main findings. Journal of human hypertension. 2011; 25(9):545–53. https://doi.org/10.1038/jhh.2010.99 PMID: 21107436

15. Sadeghi M, Talaei M, Oveisgharani S, Rabiei K, Dianatkah M, Bahonar A, et al. The cumulative incidence of conventional risk factors of cardiovascular disease and their population attributable risk in an Iranian population: The Isfahan Cohort Study. Advanced biomedical research. 2014, 3(6):138–44. Epub 2013/02/26. Eng. PMID: 23432164

16. Talaei M, Sarrafzadegan N, Sadeghi M, Oveisgharani S, Marshall T, Thomas GN, et al. Incidence of cardiovascular diseases in an Iranian population: the Isfahan Cohort Study. Arch Iran Med. 2013 Mar; 16(3):138–44. Epub 2013/02/26. Eng. PMID: 23432164

17. Khalili D, Sheikholeslami FH, Bakhityari M, Azizi F, Momenan AA, Hadaegh F. The incidence of coronary heart disease and the population attributable fraction of its risk factors in Tehran: a 10-year population-based cohort study. PloS one. 2014; 9(8):e105804. Epub 2014/08/28. Eng. https://doi.org/10.1371/journal.pone.0105804 PMID: 25162590

18. Masoudkabir F, Toghianifar N, Talaei M, Sadeghi M, Sarrafzadegan N, Mohammadifar N, et al. Socioeconomic status and incident cardiovascular disease in a developing country: findings from the Isfahan cohort study (ICS). International Journal of Public Health. 2012 June 1; 57(3):561–8. https://doi.org/10.1007/s00038-012-0344-2 PMID: 22314544

19. Nouri F, Sarrafzadegan N, Mohammadifar N, Sadeghi M, Mansourian M. Intake of legumes and the risk of cardiovascular disease: frailty modeling of a prospective cohort study in the Iranian middle-aged and older population. European journal of clinical nutrition. 2016 Feb; 70(2):217–21. Epub 2015/09/24. eng. https://doi.org/10.1038/ejcn.2015.153 PMID: 26395434

20. Sarraf-Zadegan N, Sadri G, Afzali HM, Baghaei M, Fard NM, Shahroksi S, et al. Isfahan Healthy Heart Programme: a comprehensive integrated community-based programme for cardiovascular disease prevention and control. Design, methods and initial experience. Acta cardiologica. 2003; 58(4):309–20. https://doi.org/10.2143/AC.58.4.1294036

21. Sarrafzadegan N, Kelishadi R, Baghaei A, Sadri GH, Malekafzali H, Mohammadifar N, et al. Metabolic syndrome: an emerging public health problem in Iranian women: Isfahan Healthy Heart Program. International journal of cardiology. 2008; 131(1):90–6. https://doi.org/10.1016/j.ijcard.2007.10.049 PMID: 18190978

22. D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. Jama. 2001; 286(2):180–7. PMID: 11448281

23. Liu J, Hong Y, D’Agostino RB Sr., Wu Z, Wang W, Sun J, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. Jama. 2004 Jun 2; 291(21):2591–9. Epub 2004/06/03. eng. https://doi.org/10.1001/jama.291.21.2591 PMID: 15173150
24. D’Agostino R, Nam B-H. Evaluation of the performance of survival analysis models: discrimination and calibration measures. 2003; 23:1–25.

25. Bozorgmanesh M, Hadaegh F, Zabetian A, Azizi F. San Antonio heart study diabetes prediction model applicable to a Middle Eastern population? Tehran glucose and lipid study. International journal of public health. 2010; 55(4):315–23. https://doi.org/10.1007/s00038-010-0130-y PMID: 20217177

26. World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. Geneva: World Health Organization; 2007. vi, 86 p.

27. National CGCUK. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2014.

28. Cooper A, O’Flynn N. Guidelines: risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance. BMJ: British Medical Journal. 2008; 336(7655):1246. https://doi.org/10.1136/bmj.39554.624086.AD PMID: 18511800

29. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. European heart journal. 2016; 37(29):2315–29. Epub 2016/05/31. eng.

30. Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L, Hansson L, et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clinical and experimental hypertension (New York, NY: 1993). 1999 Jul-Aug; 21(5–6):1009–60. Epub 1999/07/28. eng.

31. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 Dec 17; 106(25):3143–421. Epub 2002/12/18. eng.

32. Thomesen TF, McGee D, Davidsen M, Jorgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. International journal of epidemiology. 2002 Aug; 31(4):817–22. Epub 2002/08/15. eng. PMID: 12177028

33. Hense HW, Schulte H, Lowel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany—results from the MONICA Augsburg and the PROCAM cohorts. European heart journal. 2003 May; 24(10):937–45. Epub 2003/04/26. eng. PMID: 12714025

34. Khalili D, Hadaegh F, Soori H, Steyerberg EW, Bozorgmanesh M, Azizi F. Clinical usefulness of the Framingham cardiovascular risk profile beyond its statistical performance: the Tehran Lipid and Glucose Study. American journal of epidemiology. 2012 Aug 1; 176(3):177–86. Epub 2012/07/21. eng. https://doi.org/10.1093/aje/kws204 PMID: 22814370

35. Chow CK, Joshi R, Celemajer DS, Patel A, Neal BC. Recalibration of a Framingham risk equation for a rural population in India. Journal of epidemiology and community health. 2009 May; 63(5):379–85. Epub 2009/01/31. eng. https://doi.org/10.1136/jech.2008.077057 PMID: 19179368

36. Onat A, Can G, Herceng G, Ugur M, Yuksel H. Coronary disease risk prediction algorithm warranting incorporation of C-reactive protein in Turkish adults, manifesting sex difference. Nutrition, metabolism, and cardiovascular diseases: NMCD. 2012 Aug; 22(8):643–50. Epub 2011/02/15. eng. https://doi.org/10.1016/j.numecd.2010.10.010 PMID: 21315565

37. Goldbourt U, Yaffe S, Medalle JH. Factors predictive of long-term coronary heart disease mortality among 10,059 male Israeli civil servants and municipal employees. A 23-year mortality follow-up in the Israeli Ischemic Heart Disease Study. Cardiology. 1993; 82(2–3):100–21. Epub 1993/01/01. eng. PMID: 8324774

38. Lee J, Heng D, Chia KS, Chew SK, Tan BY, Hughes K. Risk factors and incident coronary heart disease in Chinese, Malay and Asian Indian males: the Singapore Cardiovascular Cohort Study. International journal of epidemiology. 2001 Oct; 30(5):983–8. Epub 2001/11/02. eng. PMID: 11689508

39. Jee SH, Jang Y, Oh DJ, Oh B-H, Lee SH, Park S-W, et al. A coronary heart disease prediction model: the Korean Heart Study. BMJ open. 2014; 4(5):e005025. https://doi.org/10.1136/bmjopen-2014-005025 PMID: 24848088

40. Icaza G, Núñez L, Marrugat J, Mujica V, Escobar M, Jiménez A, et al. [Estimation of coronary heart disease risk in Chilean subjects based on adapted Framingham equations]. Revista medica de Chile. 2009; 137(10):1273–82. PMID: 20011933

41. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. European heart journal. 2016; 37(29):2315–81. https://doi.org/10.1093/eurheartj/ehw106 PMID: 27222591

42. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005 Dec; 91 Suppl 5:v1–52. Epub 2005/12/21. eng.
43. Nippon DRG. Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Circulation Journal. 2006; 70(10):1249–55. PMID: 16998254

44. Zambanini A, Smith MR, Feher MD. Prediction of cardiovascular risk. Program is not suitable for diabetic patients. BMJ (Clinical research ed). 1999 May 22; 318(7195):1418; author reply 9. Epub 1999/05/20. eng.

45. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization technical report series. 2000; 894: i-xii, 1–253. Epub 2001/03/10. eng.

46. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults —The Evidence Report. National Institutes of Health. Obesity research. 1998 Sep; 6 Suppl 2:51s–209s. Epub 1998/11/14. eng.

47. Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, Thompson A, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet (London, England). 2011 Mar 26; 377(9771):1085–95. Epub 2011/03/15. eng.

48. Vasheghani-Farahani A, Majidzadeh AK, Masoudkabir F, Karbalai S, Koleini M, Aiatollahzade-Esfahani F, et al. Sagittal abdominal diameter to triceps skinfold thickness ratio: a novel anthropometric index to predict premature coronary atherosclerosis. Atherosclerosis. 2013 Apr; 227(2):329–33. Epub 2013/03/08. eng. https://doi.org/10.1016/j.atherosclerosis.2013.01.033 PMID: 23466099

49. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet (London, England). 2005 Nov 5; 366(9497):1640–9. Epub 2005/11/08. eng.

50. Talaei M, Thomas GN, Marshall T, Sadeghi M, Iranipour R, Oveisgharan S, et al. Appropriate cut-off values of waist circumference to predict cardiovascular outcomes: 7-year follow-up in an Iranian population. Internal Medicine. 2012; 51(2):139–46. PMID: 22246480

51. Sniderman AD, Bhopal R, Prabhakaran D, Sarrafzadegan N, Tchernof A. Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. International journal of epidemiology. 2007 Feb; 36(1):220–5. Epub 2007/05/19. Eng. https://doi.org/10.1093/ije/dyl245 PMID: 17510078

52. Spurlock J. Bootstrap: Responsive Web development: “O’Reilly Media, Inc.”; 2013.

53. Rogers R, Lombardo J, Mednieks Z, Meike B. Android application development: Programming with the Google SDK: O’Reilly Media, Inc.; 2009.